A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
Clinical trial NCT02141282 · COMPLETED
Trial details
- NCT number
- NCT02141282
- Sponsor
- AbbVie
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-09-10
- Primary completion
- 2021-12-22
- Enrollment
- 127
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.